Skip to main content
. 2014 Jun 23;111(27):9941–9946. doi: 10.1073/pnas.1311685111

Fig. 4.

Fig. 4.

Measurement of rhIGF1 levels and IGF1 availability. (A) Levels of rhIGF1 in serum collected 2 and 24 h after i.p. injection of rhIGF1 (unpaired t test; n animals at P28, 2 and 24 h: WT, 14 and 7; Mecp2−/y, 22 and 7; n animals at P56, 2 and 24 h: WT, 18 and 5; Mecp2−/y, 18 and 6). See Fig. S3A. Hatched bars show measurements in P56 mice after 1 wk of treatment (n = 4 each). (B) Total IGF1 concentration in blood serum collected after 2 h calculated by addition of endogenous IGF1 (filled boxes) and rhIGF1 (hatched boxes) levels for each animal. Statistics were calculated with the summed values [one-way ANOVA with Newman–Keuls post hoc analysis for multiple comparisons of treatment effects, separate analysis for each age; WT (P28 and P56), n = 12 and 10; WT+rhIGF1 (P28 and P56), n = 10 and 15; Mecp2−/y (P28 and P56), n = 10 and 9; Mecp2−/y+rhIGF1 (P28 and P56), n = 11 and 12]. Error bars represent SEM. †P < 0.1; *P < 0.05; **P < 0.01; ****P < 0.0001. See also Fig. S3.